{"filing":{"accession_number":"0001178913-26-004331","cik":"0001498403","ticker":"BLRX","company_name":"BioLineRx Ltd.","form":"6-K","filing_date":"2026-08-31","report_date":"2026-06-30","primary_document":"zk2635990.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/zk2635990.htm"},"events":[{"id":30485,"run_id":27935,"accession_number":"0001178913-26-004331","anchor_item_number":"EX-99","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release disclosing BioLineRx's unaudited financial results for the quarter ended June 30, 2026, including revenues, operating expenses, net loss, and cash position. The exhibit includes condensed consolidated interim financial statements (balance sheet, income statement, cash flows, and changes in equity) and a corporate update on clinical trial progress for GLIX1 and motixafortide. The financial results and clinical developments would materially affect a reasonable investor's assessment of the company's progress and financial condition.","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33090,"accession_number":"0001178913-26-004331","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing BioLineRx's unaudited financial results for the quarter ended June 30, 2026, including revenues, operating expenses, net loss, and cash position. The exhibit includes condensed consolidated interim financial statements (balance sheet, income statement, cash flows, and changes in equity) and a corporate update on clinical trial progress for GLIX1 and motixafortide. The financial results and clinical developments would materially affect a reasonable investor's assessment of the company's progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:16:46.524137+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33090,"accession_number":"0001178913-26-004331","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing BioLineRx's unaudited financial results for the quarter ended June 30, 2026, including revenues, operating expenses, net loss, and cash position. The exhibit includes condensed consolidated interim financial statements (balance sheet, income statement, cash flows, and changes in equity) and a corporate update on clinical trial progress for GLIX1 and motixafortide. The financial results and clinical developments would materially affect a reasonable investor's assessment of the company's progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:16:46.524137+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-31"},{"id":33091,"accession_number":"0001178913-26-004331","item_number":"EX-99#2","item_title":"exhibit_2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is BioLineRx's condensed consolidated interim financial statements (unaudited) as of June 30, 2026, covering the six-month period ended June 30, 2026. The document includes statements of financial position, comprehensive income (loss), changes in equity, and cash flows, along with supporting notes. This is a periodic interim financial report, not a discrete event or earnings press release. The filing date of August 31, 2026 is consistent with a 6-K furnishing of interim financial statements approximately two months after period-end.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:16:46.524137+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-31"},{"id":33092,"accession_number":"0001178913-26-004331","item_number":"EX-99#3","item_title":"exhibit_3.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.92,"reasoning":"This exhibit is an \"Operating and Financial Review\" section that appears to be part of a periodic financial report filed with the 6-K. The document discusses the company's product pipeline, clinical programs, and business overview as of the filing date (August 31, 2026), and explicitly references the company's \"Annual Report on Form 20-F filed on March 23, 2026.\" This is a narrative discussion accompanying interim or periodic financial statements, not a discrete event disclosure. The content is forward-looking and strategic in nature, typical of periodic reporting rather than event-driven disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:16:46.524137+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-31"}]}